Pure Global AI
NCT05901818Recruiting

Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease
Xuanwu Hospital, BeijingPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Parkinson's Disease
Drug/Device/Intervention
Autologous induced neural stem cell-derived DA precursor cells
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Xuanwu Hospital, Beijing
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jun 13, 2023
End date
Dec 31, 2026
Enrollment
10 participants
Primary outcome

Assessment of changes during the medication off time in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III, in comparison with baseline values.,Incidence and severity of transplant-related adverse events.

Summary

This is a phase I, interventional, single arm, open-label, clinical study to evaluate the
 safety and efficacy of the striatal transplantation of autologous induced neural stem
 cell-derived DA precursor cells in Parkinson's Disease patients.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismPostencephalitic parkinsonism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05901818
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05901818 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xuanwu Hospital, Beijing and is currently Recruiting. The study focuses on Parkinson's Disease. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.